Cargando…

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

Genome sequencing has uncovered an array of recurring somatic mutations in different non-Hodgkin lymphoma (NHL) subtypes. If affecting protein-coding regions, such mutations may yield mutation-derived peptides that may be presented by HLA class I proteins and recognized by cytotoxic T cells. A recur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelde, Annika, Walz, Juliane Sarah, Kowalewski, Daniel Johannes, Schuster, Heiko, Wolz, Olaf-Oliver, Peper, Janet Kerstin, Cardona Gloria, Yamel, Langerak, Anton W., Muggen, Alice F., Claus, Rainer, Bonzheim, Irina, Fend, Falko, Salih, Helmut Rainer, Kanz, Lothar, Rammensee, Hans-Georg, Stevanović, Stefan, Weber, Alexander N. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384368/ https://www.ncbi.nlm.nih.gov/pubmed/28405493 http://dx.doi.org/10.1080/2162402X.2016.1219825

Ejemplares similares

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma
por: Rodriguez, Sara, et al.
Publicado: (2022)

Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance
por: Wang, James Q., et al.
Publicado: (2014)

MYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker
por: Narasimhan, Sandhya, et al.
Publicado: (2020)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma
por: Qin, Yan, et al.
Publicado: (2023)

Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling
por: Cardona Gloria, Yamel, et al.
Publicado: (2021)

L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma
por: Mori, Naoki, et al.
Publicado: (2013)

Droplet Digital PCR Assay for MYD88(L265P): Clinical Applications in Waldenström Macroglobulinemia
por: Lo Schirico, Mariella, et al.
Publicado: (2020)

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
por: Shuai, Wen, et al.
Publicado: (2020)

MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia
por: Kim, Jung-Ah, et al.
Publicado: (2014)

Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma
por: Wenzl, Kerstin, et al.
Publicado: (2018)

MYD88(L265P) Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation
por: Ferrante, Martina, et al.
Publicado: (2021)

Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88(L265P) in Waldenström Macroglobulinemia
por: Kofides, Amanda, et al.
Publicado: (2021)

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
por: Ansell, S M, et al.
Publicado: (2014)

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation
por: Lynch, Ryan C., et al.
Publicado: (2017)

Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia
por: Drandi, Daniela, et al.
Publicado: (2018)

Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma
por: Zorofchian, Soheil, et al.
Publicado: (2018)

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2017)

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019)

Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma
por: Yamagishi, Yuki, et al.
Publicado: (2021)

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
por: Kampa-Schittenhelm, Kerstin M., et al.
Publicado: (2018)

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and “pan-leukemia” antigens
por: Backert, Linus, et al.
Publicado: (2017)

Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas
por: Shin, Sang-Yong, et al.
Publicado: (2016)

Synergistic cooperation and crosstalk between MYD88(L265P) and mutations that dysregulate CD79B and surface IgM
por: Wang, James Q., et al.
Publicado: (2017)

Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
por: Niu, Jing, et al.
Publicado: (2020)

伴MyD88 L265P突变淋巴浆细胞疾病患者的临床特征分析
Publicado: (2016)

Effectiveness of digital PCR for MYD88(L265P) detection in vitreous fluid for primary central nervous system lymphoma diagnosis
por: Chen, Kun, et al.
Publicado: (2020)

Rapid detection of the MYD88 L265P mutation for pre‐ and intra‐operative diagnosis of primary central nervous system lymphoma
por: Yamaguchi, Junya, et al.
Publicado: (2023)

Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini
por: Kowalewski, D J, et al.
Publicado: (2016)

Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization
por: Pertesi, Maroulio, et al.
Publicado: (2015)

High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment
por: Yu, Sisi, et al.
Publicado: (2018)

Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom’s macroglobulinemia: a case report
por: Barnes, Martin, et al.
Publicado: (2020)

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies
por: Çınar, Özcan, et al.
Publicado: (2021)

MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience
por: Curran, Olimpia E, et al.
Publicado: (2021)

Pyrosequencing as a Fast and Reliable Method in Detecting the MYD88 p.L265P Mutation in Decalcified Formalin-Fixed and Paraffin-Embedded Tissues
por: Gebauer, Niklas, et al.
Publicado: (2014)

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy
por: Peper, Janet Kerstin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0l9jhtdsj79lm30j1oie40lqkl